The Global Liver Fibrosis Treatment Market is expected to grow at a CAGR of 10.8% by 2026

 Liver fibrosis is a condition in which the liver is repeatedly or continuously damaged, resulting in an abnormally large quantity of scar tissue. Fibrosis has no symptoms, but severe scarring leads to cirrhosis, which causes symptoms. Healthcare providers use blood and imaging tests to determine the severity of the condition, which may be followed by a liver biopsy if necessary. Healthcare specialists focus on addressing the source of liver fibrosis, which typically stops and slows future scarring of the liver and resulting in an improvement of the condition.

Antiviral drugs, removing or dissolving a blockage in the bile ducts, lifestyle changes such as reducing alcohol consumption, controlling obesity and overweight, and controlling blood sugar and lipid levels in people with nonalcoholic fatty liver are all possible treatment options for liver fibrosis.

Furthermore, many private research organisations are projected to support research related to the development of treatments for liver fibrosis and other fatty liver diseases, which is expected to boost the liver fibrosis treatment market.For example, in August 2018, a professor from Virginia Tech's College of Science and the University of Virginia's Department of Pharmacology obtained a $400,000 grant from the Virginia Biosciences Health Research Corporation (VBHRC), with $800,000 in matching funding from Continuum Biosciences, Inc. Researchers will be

able to develop medications to treat nonalcoholic steatohepatitis with the support of this funding and matching money (NASH).

Over the projected period (2018-2026), the global liver fibrosis treatment market is expected to grow at a CAGR of 10.8%, reaching a value of US$ 28.1 billion in 2026.

In 2018, the highest market share was held by North America, followed by Europe. Obesity, type 2 diabetes, metabolic fibrosis, alcoholic fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and other potential risk factors for liver fibrosis are all on the rise. In comparison to the obesity and type 2 diabetes epidemics, NAFLD is the most common chronic liver ailment in Western populations of economies in Europe and the United States, according to the NASH Education Program's 2018 data findings. Furthermore, between 2015 and 2030, the prevalence of NASH is anticipated to rise by 63 percent, resulting in NASH become a major cause of liver transplantation in the U.S. by 2020.

Furthermore, the World Health Organization (WHO) estimates that more than 1.9 billion persons aged 18 and up were overweight in 2016, with around 650 million being obese. Obesity levels are expected to be particularly high in the United States, Mexico, and the United Kingdom, according to the Organisation for Economic Co-operation and Development (OECD): Obesity Update 2017 report, with 47 percent, 39 percent, and 35 percent of the population obese in 2030, respectively.

Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., and FibroGen, Inc. are some of the major competitors in the liver fibrosis treatment industry.